Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company's lead product...